Risk Factors for Asymptomatic Ventricular Dysfunction in Rheumatoid Arthritis Patients

Table 2

Comparison of clinical and biochemical characteristics between rheumatoid arthritis patients with and without ventricular dysfunction.

Variables	Ventricular dysfunction; 𝑛=57	No ventricular dysfunction; 𝑛=48	𝑃
Age (years)	65.4±14.1	58.8±14.6	0.02
Habitual weight (kg)	65.1±10.9	63.0±11.2	0.36
Body mass index (kg/m^2)	23.6±9.1	24.0±8.8	0.83
Rheumatoid arthritis evolution time	18.87±12.54	15.09±11.12	0.11
Cancer (%)	9.6	14	0.51
Coronary artery disease (%)	45.3	11.9	<0.0001
Obesity (%)	21.2	25	0.65
Diabetes (%)	26.4	9.3	0.03
Dyslipidemia (%)	11.5	32.6	0.01
Hypertension (%)	56.6	54.5	0.84
Nephropathy (%)	15.1	14	0.87
Albumin (mg/dL)	3.34±0.67	3.41±0.52	0.38
Hemoglobin (g/dL)	12.7±2.1	13.1±2.0	0.39
Hematocrit (%)	38.1±6.1	38.9±5.7	0.39
Total cholesterol (mg/dL)	173.0±54.4	177.3±37.0	0.047
c-LDL (mg/dL)	107.2±43.0	101.0±23.0	0.005
c-HDL (mg/dL)	42.6±13.6	42.3±13.2	0.78
Triglycerides (mg/dL)	129.2±59.5	159.0±87.7	0.04
DAS28 questionnaire	4.74±1.13	4.53±1.31	0.18
Rheumatoid factor UI/dL	96.5 (63.9–631.7)	37 (20.8–220.8)	0.03
Anti-CCP antibody	264 (23–136.5)	114 (18.9–784.3)	0.34
C-reactive protein	1.65 (0.89–2.85)	1.03 (0.57–4.08)	0.34
ESR (mm/hr)	29 (18–48.8)	33 (18.8–57)	0.5
Functional capacity
Stage 1	18 (36)	24 (53.3)
Stage 2	24 (48)	12 (26.7)	0.13
Stage 3	8 (16)	8 (17.8)

Anti-CCP: anticyclic citrullinated peptide antibodies; ESR: erythrocyte sedimentation rate.
Data are expressed as %, mean ± standard deviation, or median (percentile 50–75).